)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Stayble Therapeutics
Stayble Therapeutics (STABL) investor relations material
Stayble Therapeutics has been delisted
Stayble Therapeutics Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary21 May, 2026
Executive summary
No significant events were communicated during Q1 2026, but active work on financing and phase 2b preparations continued.
After the period, a control balance sheet was established as equity fell below half of registered share capital.
A non-binding term sheet for strategic collaboration and financing was signed in May, with ongoing efforts to secure binding investment.
The company continues preparations for a phase 2b study of STA363, targeting chronic disc herniation pain.
Financial highlights
Operating costs for Q1 2026 were 5,859 KSEK, up from 2,066 KSEK in Q1 2025.
EBIT for Q1 2026 was -5,854 KSEK, compared to -2,044 KSEK in Q1 2025.
Net result for Q1 2026 was -5,862 KSEK, versus -2,044 KSEK in Q1 2025.
Cash and cash equivalents at March 31, 2026, were 1,102 KSEK, down from 2,570 KSEK a year earlier.
Equity at March 31, 2026, was 1,060 KSEK, below half of the registered share capital of 4,184 KSEK.
Outlook and guidance
Liquid assets are sufficient for operations until June 2026; ongoing discussions for further financing.
Focus remains on converting the term sheet into a binding investment agreement and securing phase 2b funding.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Stayble Therapeutics
- Improved financials and extended runway support STA363's next clinical phase and funding efforts.STABL
Q4 2025 - Operating losses narrowed and funding secured as STA363 advances to phase 2 trials.STABLQ2 2025
- Phase 1b success for STA363 drives phase 2 planning and partnership focus.STABLQ3 2024
- Interim data confirm STA363 safety; final phase 1b results expected Q4 2024.STABLQ2 2024
- Q1 2025 saw improved results, new funding, and strong momentum for STA363 partnerships.STABLQ1 2025
- Positive clinical data, improved financials, and new capital drive STA363 partnership prospects.STABLQ4 2024
Stayble Therapeutics
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Stayble Therapeutics is a clinical-stage biotechnology company developing non-surgical treatments for chronic disc-related back pain. Its lead candidate targets degenerative disc disease using injectable therapeutics. The company is headquartered in Gothenburg, Sweden, and its shares are listed on the Nasdaq First North Growth Market.